(March 28, 2018) Biscayne Neurotherapeutics Licenses Rights to its Novel Antiepileptic Agent to Global Drug Development Centre (GDCC) China. Separately, Biscayne Announces Start of Phase 2 Trial in Most Common Type of Adult Epilepsy.
(October 19, 2017) Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results for Its Novel Anti-epileptic Agent
(May 9, 2017 ) Biscayne Readies Phase 1B Trial For Novel Antiepileptic Agent BIS-001 And Receives FDA Orphan Drug Designation For Dravet Syndrome
(January 27, 2017) Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
(October 24, 2016) Newly Published Data Show Biscayne Pharmaceuticals’ Novel Antiepileptic Drug Can Eliminate Seizures in Models of Dravet Syndrome
(December 7, 2015) Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent Bis-001 At Eilat Conference On New Antiepileptic Drugs
(May 9 , 2017) Biscayne Pharmaceuticals Presents Data At 2015 Aes Meeting Confirming Bis-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug